Switch theme
Sign up to access all valuation multiples
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
2001
9
LTM Revenue $0.2M
LTM EBITDA -$20.8M
$10.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Incannex has a last 12-month revenue (LTM) of $0.2M and a last 12-month EBITDA of -$20.8M.
In the most recent fiscal year, Incannex achieved revenue of $12K and an EBITDA of -$18.5M.
Incannex expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Incannex valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | XXX | $12K | XXX | XXX | XXX |
| Gross Profit | $0.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$20.8M | XXX | -$18.5M | XXX | XXX | XXX |
| EBITDA Margin | -11263% | XXX | -154200% | XXX | XXX | XXX |
| EBIT | -$23.4M | XXX | -$18.6M | XXX | XXX | XXX |
| EBIT Margin | -12675% | XXX | -155058% | XXX | XXX | XXX |
| Net Profit | -$20.8M | XXX | -$18.5M | XXX | XXX | XXX |
| Net Margin | -11266% | XXX | -153825% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Incannex's stock price is $0.
Incannex has current market cap of $15.3M, and EV of $10.3M.
See Incannex trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.3M | $15.3M | XXX | XXX | XXX | XXX | $-0.98 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Incannex has market cap of $15.3M and EV of $10.3M.
Incannex's trades at 96.8x EV/Revenue multiple, and -0.5x EV/EBITDA.
Equity research analysts estimate Incannex's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Incannex has a P/E ratio of -0.7x.
See valuation multiples for Incannex and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15.3M | XXX | $15.3M | XXX | XXX | XXX |
| EV (current) | $10.3M | XXX | $10.3M | XXX | XXX | XXX |
| EV/Revenue | 55.6x | XXX | 96.8x | XXX | XXX | XXX |
| EV/EBITDA | -0.5x | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.5x | XXX | XXX | XXX |
| EV/Gross Profit | 55.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.7x | XXX | -0.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIncannex's last 12 month revenue growth is 257%
Incannex's revenue per employee in the last FY averaged $1K, while opex per employee averaged $2.1M for the same period.
Incannex's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Incannex's rule of X is -10621% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Incannex and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 257% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -11263% | XXX | -18634% | XXX | XXX | XXX |
| EBITDA Growth | 58% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -18377% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -10621% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8792% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 107325% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 155158% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Incannex acquired XXX companies to date.
Last acquisition by Incannex was XXXXXXXX, XXXXX XXXXX XXXXXX . Incannex acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Incannex founded? | Incannex was founded in 2001. |
| Where is Incannex headquartered? | Incannex is headquartered in United States of America. |
| How many employees does Incannex have? | As of today, Incannex has 9 employees. |
| Who is the CEO of Incannex? | Incannex's CEO is Mr. Joel Latham. |
| Is Incannex publicy listed? | Yes, Incannex is a public company listed on NAS. |
| What is the stock symbol of Incannex? | Incannex trades under IXHL ticker. |
| When did Incannex go public? | Incannex went public in 2022. |
| Who are competitors of Incannex? | Similar companies to Incannex include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Incannex? | Incannex's current market cap is $15.3M |
| What is the current revenue of Incannex? | Incannex's last 12 months revenue is $0.2M. |
| What is the current revenue growth of Incannex? | Incannex revenue growth (NTM/LTM) is 257%. |
| What is the current EV/Revenue multiple of Incannex? | Current revenue multiple of Incannex is 55.6x. |
| Is Incannex profitable? | Yes, Incannex is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Incannex? | Incannex's last 12 months EBITDA is -$20.8M. |
| What is Incannex's EBITDA margin? | Incannex's last 12 months EBITDA margin is -11263%. |
| What is the current EV/EBITDA multiple of Incannex? | Current EBITDA multiple of Incannex is -0.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
